This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jorge Litvak, MD
International University Exchange, Inc Washington, DC

JAMA. 1996;276(2):102-103.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Hennekens and colleagues¹ is certainly a significant contribution to the controversial data on the association between breast implants and connectivetissue disease. The authors recognize that further research is still necessary before firm conclusions can be drawn, particularly because they targeted classic connective-tissue diseases and did not assess the occurrence of atypical connectivetissue disease causing symptoms that are common to many women with implants.²

However, the purpose of this letter is not directly related to the results of this excellently designed retrospective cohort study, but to an ethical question that puzzled me after reading the sources of funding of the study. While research funding from private industry is to be commended, in this particular case, financial support was received from Dow Corning, one of the manufacturers of silicone breast implants. This company has been in litigation regularly in the last few years as defendants in . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?